Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

NCT01187966 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

669

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: Safinamide
DRUG: Safinamide
DRUG: Placebo

Sponsor

Newron Pharmaceuticals SPA